

7. (Amended) A polynucleotide according to claim 6, wherein the polypeptide comprises an immunoglobulin variable region [is from a light chain] containing the three light chain CDRs of antibody 11D10.

8. (Amended) A polynucleotide according to claim 6, wherein the polypeptide comprises an immunoglobulin variable region [is from a heavy chain] containing the three heavy chain CDRs of antibody 11D10.

9. (Amended) The [isolated] polynucleotide of claim 6, wherein the [5 contiguous amino acids] immunoglobulin variable region [are depicted] is contained [within] in SEQ ID NO:2.

10. (Amended) The [isolated] polynucleotide of claim 6, wherein the [5 contiguous amino acids] immunoglobulin variable region [are depicted] is contained [within] in SEQ ID NO:4.

11. (Amended) The [isolated] polynucleotide of claim 6, wherein the encoding sequence is [depicted] contained [within] in the variable in region encoding sequence in SEQ ID NO:1.

12. (Amended) The [isolated] polynucleotide of claim 6, wherein the encoding sequence is [depicted] contained [within] in the variable region encoding sequence in SEQ ID NO:3.

14. (Amended) A[n isolated] polynucleotide comprising a region of at least 15 contiguous nucleotides of the sequence contained in SEQ ID NO:1, said region [capable of] forming a stable duplex with a polynucleotide consisting of the light chain variable encoding sequence of SEQ ID NO:1 under hybridization conditions [where the region does not form a stable hybrid with SEQ ID NO:5 through SEQ ID NO:14] of 68°C and 0.15 M NaCl and 15 mM citrate buffer (1 X SSC).

15. (Amended) A[n isolated polynucleotide] comprising a region of at least 15 contiguous nucleotides of the sequence contained in SEQ ID NO:3, said region [capable of] forming a stable duplex with a polynucleotide consisting of the heavy chain variable encoding sequence of SEQ ID NO:3 under hybridization conditions [where the region does not form a stable hybrid with

Seq C3
SEQ ID NO:15 through SEQ ID NO:32] of 68°C and 0.15 M NaCl and 15 mM citrate buffer (1 X SSC).

Seq C3
16. (Amended) A polynucleotide according to claim 6, wherein the polynucleotide is a cloning vector.

Seq C3
17. (Amended) A polynucleotide according to claim 6, wherein the polynucleotide is an expression vector.

Seq C3
18. (Amended) The expression vector of claim 17, wherein the expression vector is vaccinia.

Seq C4
19. (Amended) A host cell comprising the polynucleotide of claim 6, wherein the polynucleotide is a recombinant polynucleotide.

Seq C5
38. (Amended) A [pharmaceutical] composition comprising [an effective amount of] the polynucleotide of claim 6 and a pharmaceutically acceptable excipient.

Seq C5
41. (Amended) An immunogenic composition [vaccine] comprising [an effective amount of] the polynucleotide of claim 6 and a pharmaceutically acceptable excipient.

Seq C5
44. (Amended) The [vaccine] immunogenic composition of claim [38] 41, wherein the [vaccine] immunogenic composition [is] comprises a live virus or viral expression vector.

Seq C5
45. (Amended) The [vaccine] immunogenic composition of claim 44, wherein the [vaccine] immunogenic composition is vaccinia.

Seq C5
59. (New) The polynucleotide of claim 6, wherein antibody 11D10 has the light and heavy chain variable region sequences contained in SEQ ID NO:2 and SEQ ID NO:4, respectively.

Seq C5
60. (New) The composition of claim 38, further comprising an amount of the polynucleotide sufficient to elicit an anti-HMFG immunological response.